Bacterial co-infections and antibiotic prescribing practice in adults with COVID-19: experience from a single hospital cluster

被引:31
作者
Cheng, Lily Shui-kuen [1 ]
Chau, Sandy Ka-yee [2 ]
Tso, Eugene Yuk-keung [3 ]
Tsang, Steven Woon-choy [4 ]
Li, Issac Yuk-fai [5 ]
Wong, Barry Kin-chung [2 ]
Fung, Kitty Sau-chun [2 ]
机构
[1] United Christian Hosp, Dept Pathol, Kwun Tong, Kowloon, 130 Hip Wo St, Hong Kong, Peoples R China
[2] United Christian Hosp, Dept Pathol, Hong Kong, Peoples R China
[3] United Christian Hosp, Dept Med & Geriatr, Hong Kong, Peoples R China
[4] Tseung Kwan O Hosp, Dept Med, Hong Kong, Peoples R China
[5] Tseung Kwan O Hosp, Dept Pathol, Hong Kong, Peoples R China
关键词
antibiotics; antimicrobial stewardship; bacterial co-infection; COVID-19; SARS-CoV-2; COMMUNITY-ACQUIRED PNEUMONIA; DISEASE; 2019; COVID-19; PANDEMIC INFLUENZA; CLINICAL CHARACTERISTICS; PROCALCITONIN; INFECTIONS; ETIOLOGY;
D O I
10.1177/2049936120978095
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected millions of individuals since December 2019, resulting in significant morbidity and mortality globally. During the 1918 Influenza Pandemic, it was observed that influenza was associated with bacterial co-infections. However, empirical or prophylactic antibiotic use during viral pandemics should be balanced against the associated adverse drug events. Methods: In this retrospective cohort study, we investigated bacterial co-infections in adults with COVID-19 in Hong Kong. Notably, at the time of writing this report, patients with varying disease severities were isolated in hospitals until confirmatory evidence of virological clearance or immunity was available. The study included adults with laboratory-confirmed COVID-19 admitted to a single hospital cluster between 8 January 2020 and 1 May 2020. We obtained data regarding patient demographics, clinical presentations, blood test results, treatment, and outcomes. Bacteriological profiles and risk factors for co-infections were investigated. Antibiotic prescription practices were also reviewed. Results: Of the 147 patients recruited, clinical disease was suspected in 42% (n = 62) of patients who underwent testing for other respiratory infections. Notably, 35% (n = 52) of the patients were prescribed empirical antibiotics, predominantly penicillins or cephalosporins. Of these, 35% (n = 18) received more than one class of antibiotics and 37% (n = 19) received empirical antibiotics for over 1 week. Overall, 8.2% (n = 12) of patients developed bacterial co-infections since the detection of COVID-19 until discharge. Methicillin-susceptible Staphylococcus aureus was the most common causative pathogen identified. Although 8.2% (n = 12) of patients developed hypoxia and required oxygen therapy, no mortality was observed. Multivariate analysis showed that pneumonic changes on chest radiography at the time of admission predicted bacterial co-infections. Conclusion: These findings emphasise the importance of judicious administration of antibiotics throughout the disease course of COVID-19 and highlight the role of antimicrobial stewardship during a pandemic.
引用
收藏
页数:12
相关论文
共 35 条
  • [1] SARS-CoV-2 in Spanish Intensive Care Units: Early experience with 15-day survival in Vitoria
    Barrasa, Helena
    Rello, Jordi
    Tejada, Sofia
    Martin, Alejandro
    Balziskueta, Goiatz
    Vinuesa, Cristina
    Fernandez-Miret, Borja
    Villagra, Ana
    Vallejo, Ana
    San Sebastian, Ana
    Cabanes, Sara
    Iribarren, Sebastian
    Fonseca, Fernando
    Maynar, Javier
    [J]. ANAESTHESIA CRITICAL CARE & PAIN MEDICINE, 2020, 39 (05) : 553 - 561
  • [2] Deaths from bacterial pneumonia during 1918-19 influenza pandemic
    Brundage, John F.
    Shanks, G. Dennis
    [J]. EMERGING INFECTIOUS DISEASES, 2008, 14 (08) : 1193 - 1199
  • [3] Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
    Chen, Nanshan
    Zhou, Min
    Dong, Xuan
    Qu, Jieming
    Gong, Fengyun
    Han, Yang
    Qiu, Yang
    Wang, Jingli
    Liu, Ying
    Wei, Yuan
    Xia, Jia'an
    Yu, Ting
    Zhang, Xinxin
    Zhang, Li
    [J]. LANCET, 2020, 395 (10223) : 507 - 513
  • [4] Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia a Randomized trial
    Christ-Crain, Miriam
    Stolz, Daiana
    Bingisser, Roland
    Muller, Christian
    Miedinger, David
    Huber, Peter R.
    Zimmerli, Werner
    Harbarth, Stephan
    Tamm, Michael
    Mueller, Beat
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2006, 174 (01) : 84 - 93
  • [5] Coronavirus Disease 2019, Superinfections, and Antimicrobial Development: What Can We Expect?
    Clancy, Cornelius J.
    Nguyen, M. Hong
    [J]. CLINICAL INFECTIOUS DISEASES, 2020, 71 (10) : 2736 - 2743
  • [6] Epidemiology and clinical characteristics of hospitalized patients with pandemic influenza A (H1N1) 2009 infections: the effects of bacterial coinfection
    Dhanoa, Amreeta
    Fang, Ngim C.
    Hassan, Sharifah S.
    Kaniappan, Priyatharisni
    Rajasekaram, Ganeswrie
    [J]. VIROLOGY JOURNAL, 2011, 8
  • [7] Panton-Valentine Leukocidin-Secreting Staphylococcus aureus Pneumonia Complicating COVID-19
    Duployez, Claire
    Le Guern, Remi
    Tinez, Claire
    Lejeune, Anne-Laure
    Robriquet, Laurent
    Six, Sophie
    Loiez, Caroline
    Wallet, Frederic
    [J]. EMERGING INFECTIOUS DISEASES, 2020, 26 (08) : 1939 - 1941
  • [8] Procalcitonin and C-reactive protein levels in community-acquired pneumonia: Correlation with etiology and prognosis
    Hedlund, J
    Hansson, LO
    [J]. INFECTION, 2000, 28 (02) : 68 - 73
  • [9] How covid-19 is accelerating the threat of antimicrobial resistance
    Hsu, Jeremy
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2020, 369
  • [10] Huang CL, 2020, LANCET, V395, P497, DOI [10.1016/S0140-6736(20)30211-7, 10.1016/S0140-6736(20)30183-5]